Screening for Dementia: Summary of the Evidence. Table 4. Efficacy of Cholinesterase Inhibitors in Patients with Alzheimer's Disease After 3 to 12 Months

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Screening: Dementia > Summary of the Evidence

Drug (reference)	Patients, n	Cognitive function¹	Clinician-assessed global function²	Physical function as assessed by IADLs
Tacrine⁷⁴	1,984	1.36 to 2.78, sig.	1.18 to 2.11, sig.	Inconclusive
Donepezil^{73;76;77;79;80}	1,980	2.12 to 3.01, sig.	2.04 to 2.63, sig.	Inconclusive
Rivastigmine^72;78	4,095	2.28 to 2.4, sig.	1.4 to 2.36, sig.	Inconclusive
Galantamine⁷⁵	1,674	3.00 to 3.4, sig.	1.71 to 1.94, sig.	Inconclusive
Note: sig. indicates statistically significant. ¹The mean difference between drug and placebo on the Alzheimer's Disease Assessment Scale for Cognition, a 70-point scale. ²The odds ratio for having at least stable range of global function after treatment with drug in comparison with placebo as measured by the Clinician's Interview Based Impression of Change, plus caregiver input scale (CIBIC).